TG Therapeutics Inc

-0.29 (-0.77%)

Tg Therapeutics Announces FDA Acceptance Of Biologics License Application For Ublituximab In Combination With Ukoniq® (Umbralisib)

Published: 05/25/2021 11:13 GMT
TG Therapeutics Inc (TGTX) - Tg Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination With Ukoniq® (umbralisib) As a Treatment for Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
Tg Therapeutics Inc - FDA Has Set a Prescription Drug User Fee Act (pdufa) Goal Date of March 25, 2022.
Tg Therapeutics - FDA Also Notified Co That It is Not Currently Planning to Hold an Advisory Committee Meeting to Discuss Application.